The efficacy and drug survival of the biosimilar infliximab (ct-p13) compared to the original reference infliximab in inflammatory rheumatic diseases; Results from the turkbio registry

Uslu, SadettinCan, GerçekŞenel, Sonerİnanç, NevsunAkars, ServetKocaer, Sinem BurcuBirlik, MerihCapar, SedatAkkoç, NurullahÖnen, Fatoş2024-01-082024-01-082018-09Uslu, S. vd. (2018). ''The efficacy and drug survival of the biosimilar infliximab (ct-p13) compared to the original reference infliximab in inflammatory rheumatic diseases; Results from the turkbio registry''. Arthritis & Rheumatology, 70(Supplement 9).2326-51912326-5205https://hdl.handle.net/11452/38832eninfo:eu-repo/semantics/closedAccessRheumatologyThe efficacy and drug survival of the biosimilar infliximab (ct-p13) compared to the original reference infliximab in inflammatory rheumatic diseases; Results from the turkbio registryArticle00044726890426570Supplement 9Rheumatology